EPCAM and cancer: The PEG layer can increase its systemic circulation, inhibit the removal of NPs by the mononuclear phagocytic system, and alter some physicochemical properties of the NPs, such as stability, and drug loading and release conduct, while the EpCAM moiety is aimed to increase the targeting of nanocarriers for cancer cells.